Opendata, web and dolomites

NOVA-MRI SIGNED

Novel Applications in 19F Magnetic Resonance Imaging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOVA-MRI project word cloud

Explore the words cloud of the NOVA-MRI project. It provides you a very rough idea of what is the project "NOVA-MRI" about.

trafficking    safe    tissue    payload    door    resolution    materials    incorporated    labelled    generation    ligands    background    inside    nanoparticles    tissues    individual    accumulated    limit    absolutely    surrounding    therapeutic    imaging    mounting    expansion    biology    accumulate    competing    discrimination    insights    brain    risk    impairment    cell    safety    professionals    regarding    preclinical    opened    novelty    resonance    living    magnetic    deposits    invasive    gadolinium    perfluorocarbon    migration    area    2015    gbca    tolerated    healthcare    visualised    cells    historically    functionalisation    announcement    basis    19f    deemed    signal    diagnostic    modality    kidneys    gbcas    generally    molecular    move    quantitative    animals    clinical    bone    agents    multifunctional    smart    body    active    whilst    signatures    patients    contrast    released    administered    biomaterial    found    situations    reagents    renal    advised    mri    until    spurred    repeated    technique    structures    fda    imaged   

Project "NOVA-MRI" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS LEIDEN 

Organization address
address: ALBINUSDREEF 2
city: LEIDEN
postcode: 2333 ZA
website: www.lumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 4˙051˙634 €
 EC max contribution 4˙051˙634 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) coordinator 796˙859.00
2    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 606˙345.00
3    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 303˙172.00
4    POLYPURE AS NO (OSLO) participant 292˙342.00
5    PERCUROS BV NL (LEIDEN) participant 265˙619.00
6    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 265˙619.00
7    UNIVERSITA DEGLI STUDI DI CAMERINO IT (CAMERINO) participant 261˙499.00
8    CROZET MEDICAL GMBH DE (DUSSELDORF) participant 252˙788.00
9    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF DE (DUSSELDORF) participant 252˙788.00
10    MEDRES-MEDICAL RESEARCH GMBH DE (KOLN) participant 252˙788.00
11    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE ES (SAN SEBASTIAN) participant 250˙904.00
12    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 250˙904.00

Map

 Project objective

Magnetic resonance imaging (MRI) is a leading clinical diagnostic technique that is able to provide whole body imaging, and when individual cells are imaged in living animals, it can provide new insights into the biology of cell trafficking and migration. For cells to be visualised by MRI, they generally must be labelled to enable their discrimination from surrounding tissue. The development of magnetic resonance imaging (MRI) contrast agents is therefore an active area of research, where the basis for this interest is the expansion of MRI as a high-resolution and non-invasive important preclinical and clinical imaging modality. Moreover, there are now new opportunities to developing smart materials with multifunctional abilities including MRI contrast in-built within biomaterial structures, functionalisation with targeting ligands and the carrying of a therapeutic payload. This move towards a new generation of MRI contrast reagents has also been spurred on by the mounting evidence against gadolinium-based contrast agents (GBCAs). They are currently the agents of choice and were considered historically safe and well tolerated until recently. However, they have been found to accumulate in various tissues of patients who do not have renal impairment, including bone, brain and kidneys. Furthermore, in 2015, the FDA released a new safety announcement regarding GBCAs and the risk of accumulated deposits in the brain following repeated use. Whilst GBCAs are being investigated, they can still be administered but healthcare professionals have been advised to limit the use of GBCA to situations in which contrast is deemed absolutely necessary.This has opened the door to the novelty of using perfluorocarbon (19F) being incorporated inside smart nanoparticles, which can offer unique quantitative signatures for molecular MRI with no competing background signal.

 Publications

year authors and title journal last update
List of publications.
2020 Somayeh Rezaei, Soheila Kashanian, Yadollah Bahrami, Luis J. Cruz, Marjan Motiei
Redox-Sensitive and Hyaluronic Acid-Functionalized Nanoparticles for Improving Breast Cancer Treatment by Cytoplasmic 17α-Methyltestosterone Delivery
published pages: 1181, ISSN: 1420-3049, DOI: 10.3390/molecules25051181
Molecules 25/5 2020-04-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVA-MRI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVA-MRI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ARCH (2019)

AGE-RELATED CHANGES IN HEMATOPOIESIS

Read More  

CHANGE (2019)

Cultural Heritage Analysis for New GEnerations

Read More  

DELIVER (2019)

DELIVERy of advanced therapies for diabetes training network

Read More